Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth.

doi:10.1002/cmdc.202100032

Paper

Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth.

Published Apr 8, 2021 · D. Gnocchi, M. M. Cavalluzzi, G. Mangiatordi

ChemMedChem

Q1 SJR score

8

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Despite the increasing incidence of Hepatocellular carcinoma (HCC) worldwide, current pharmacological treatments are still unsatisfactory. We have previously shown that lysophosphatidic acid receptor 6 (LPAR6) supports HCC growth and that 9-xanthenylacetic acid (XAA) acts as an LPAR6 antagonist inhibiting HCC growth without toxicity. Here, we synthesized four novel XAA derivatives, (±)-2-(9H-xanthen-9-yl)propanoic acid (compound 4 - MC9), (±)-2-(9H-xanthen-9-yl)butanoic acid (compound 5 - MC6), (±)-2-(9H-xanthen-9-yl)hexanoic acid (compound 7 - MC11), and (±)-2-(9H-xanthen-9-yl)octanoic acid (compound 8 - MC12, sodium salt) by introducing alkyl groups of increasing length at the acetic α-carbon atom. Two of these compounds were characterized by X-ray powder diffraction and quantum mechanical calculations, while molecular docking simulations suggested their enantioselectivity for LPAR6. Biological data showed anti-HCC activity for all XAA derivatives, with the maximum effect observed for MC11. Our findings support the view that increasing the length of the alkyl group improves the inhibitory action of XAA and that enantioselectivity can be exploited for designing novel and more effective XAA-based LPAR6 antagonists.

In Vitro Study

Study Snapshot

Xanthenylacetic acid derivatives with increasing alkyl groups improve the inhibitory action of XAA against liver cancer cell growth, offering potential for novel and more effective LPAR6 antagonists.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth.

Sign up to use Study Snapshot

References

Citations

hERG stereoselective modulation by mexiletine‐derived ureas: Molecular docking study, synthesis, and biological evaluation

The mexiletine-derived urea 8 shows potential in treating both congenital and drug-induced forms of long QT syndrome by selectively modulating the hERG potassium channel.

Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline‐deficient l‐amino acid‐defined diet prevents hepatocarcinogenesis in mice

Inhibiting LPAR6 by 9-xanthylacetic acid prevents hepatocarcinogenesis in mice by counteracting metabolic imbalances caused by the choline-deficient l-amino acid-defined diet.

Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy

A multi-target metabolic approach may offer a promising new option for treating hepatocellular carcinoma (HCC), as current therapies are aggressive and not curative.

Lactic fermentation: A maladaptive mechanism and an evolutionary throwback boosting cancer drug resistance.

Chronic or high-dose chemotherapy can trigger, enhance, and sustain metabolic reprogramming in cancer cells, potentially boosting chemotherapy resistance.

Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.

Inhibiting LPAR6 can overcome sorafenib resistance in hepatocellular carcinoma by switching glycolysis into oxidative phosphorylation.